MX2019013160A - Metodos de tratamiento selectivo del asma usando antagonistas de il-17. - Google Patents
Metodos de tratamiento selectivo del asma usando antagonistas de il-17.Info
- Publication number
- MX2019013160A MX2019013160A MX2019013160A MX2019013160A MX2019013160A MX 2019013160 A MX2019013160 A MX 2019013160A MX 2019013160 A MX2019013160 A MX 2019013160A MX 2019013160 A MX2019013160 A MX 2019013160A MX 2019013160 A MX2019013160 A MX 2019013160A
- Authority
- MX
- Mexico
- Prior art keywords
- antagonists
- methods
- treating asthma
- selectively treating
- asthma
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762501806P | 2017-05-05 | 2017-05-05 | |
| PCT/IB2018/053106 WO2018203289A1 (en) | 2017-05-05 | 2018-05-04 | Methods of selectively treating asthma using il-17 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019013160A true MX2019013160A (es) | 2020-02-05 |
Family
ID=62245372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013160A MX2019013160A (es) | 2017-05-05 | 2018-05-04 | Metodos de tratamiento selectivo del asma usando antagonistas de il-17. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10676522B2 (enExample) |
| EP (1) | EP3619536A1 (enExample) |
| JP (1) | JP2020518604A (enExample) |
| KR (1) | KR20190142398A (enExample) |
| CN (1) | CN110582702A (enExample) |
| AU (1) | AU2018263159A1 (enExample) |
| BR (1) | BR112019023141A2 (enExample) |
| CA (1) | CA3062179A1 (enExample) |
| CL (1) | CL2019003161A1 (enExample) |
| MX (1) | MX2019013160A (enExample) |
| RU (1) | RU2019139387A (enExample) |
| TW (1) | TW201842933A (enExample) |
| WO (1) | WO2018203289A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3689907A1 (en) * | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
| WO2021211430A1 (en) * | 2020-04-17 | 2021-10-21 | Eli Lilly And Company | Treatment of respiratory disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0308324D0 (en) | 2003-04-10 | 2003-05-14 | Piezoptic Ltd | A chemical sensing device |
| CN1898564A (zh) * | 2003-12-24 | 2007-01-17 | 惠氏公司 | 治疗哮喘的方法 |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| CN101326195B9 (zh) | 2005-12-13 | 2022-11-11 | 伊莱利利公司 | 抗il-17抗体 |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| JP6161233B2 (ja) | 2008-03-31 | 2017-07-12 | ジェネンテック， インコーポレイテッド | 喘息の治療及び診断のための組成物及び方法 |
| KR101318549B1 (ko) | 2008-09-29 | 2013-10-16 | 로슈 글리카트 아게 | 인간 ｉｌ17 에 대한 항체 및 이의 용도 |
| MX371052B (es) | 2013-02-08 | 2020-01-14 | Novartis Ag | Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios. |
| BR112016008694A2 (pt) * | 2013-10-23 | 2017-10-03 | Genentech Inc | Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit |
| WO2015191783A2 (en) * | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| US11278618B2 (en) * | 2014-09-10 | 2022-03-22 | Novartis Ag | Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients |
| GB201508832D0 (en) | 2015-05-22 | 2015-07-01 | Novartis Ag | A method for detecting an analyte |
-
2018
- 2018-05-03 TW TW107114983A patent/TW201842933A/zh unknown
- 2018-05-03 US US15/969,952 patent/US10676522B2/en active Active
- 2018-05-04 JP JP2019560115A patent/JP2020518604A/ja active Pending
- 2018-05-04 CA CA3062179A patent/CA3062179A1/en not_active Abandoned
- 2018-05-04 RU RU2019139387A patent/RU2019139387A/ru not_active Application Discontinuation
- 2018-05-04 KR KR1020197035578A patent/KR20190142398A/ko not_active Abandoned
- 2018-05-04 CN CN201880029544.7A patent/CN110582702A/zh active Pending
- 2018-05-04 EP EP18727435.2A patent/EP3619536A1/en not_active Withdrawn
- 2018-05-04 AU AU2018263159A patent/AU2018263159A1/en not_active Abandoned
- 2018-05-04 MX MX2019013160A patent/MX2019013160A/es unknown
- 2018-05-04 BR BR112019023141-2A patent/BR112019023141A2/pt not_active Application Discontinuation
- 2018-05-04 WO PCT/IB2018/053106 patent/WO2018203289A1/en not_active Ceased
-
2019
- 2019-11-04 CL CL2019003161A patent/CL2019003161A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2019003161A1 (es) | 2020-02-07 |
| BR112019023141A2 (pt) | 2020-07-28 |
| TW201842933A (zh) | 2018-12-16 |
| JP2020518604A (ja) | 2020-06-25 |
| US20180319881A1 (en) | 2018-11-08 |
| KR20190142398A (ko) | 2019-12-26 |
| RU2019139387A (ru) | 2021-06-07 |
| CN110582702A (zh) | 2019-12-17 |
| CA3062179A1 (en) | 2018-11-08 |
| EP3619536A1 (en) | 2020-03-11 |
| US10676522B2 (en) | 2020-06-09 |
| AU2018263159A1 (en) | 2019-11-07 |
| WO2018203289A1 (en) | 2018-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201491011A1 (ru) | Способы лечения с помощью ингибитора гамма-интерферона | |
| PH12019502331A1 (en) | Treatment of asthma with anti-tslp antibody | |
| NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| PH12018500810A1 (en) | Antibody agents specific for human cd19 and uses thereof | |
| HK1250752A1 (zh) | 治疗骨髓增生性障碍的方法 | |
| EA201690746A1 (ru) | Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии | |
| MX2016005159A (es) | Metodos de diagnostico y tratamiento de trastornos eosinofilicos. | |
| MY163057A (en) | Means and methods for trating dlblcl | |
| TN2015000050A1 (en) | Methods of treating a tauopathy | |
| EA201790195A1 (ru) | Способы лечения рака с применением ингибиторов tigit и противораковых агентов | |
| EA201691683A1 (ru) | Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме | |
| WO2014138429A3 (en) | Peptidomimetic macrocycles and use thereof in regulating hif1alpha | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| TW201612189A (en) | Sterile chromatography and manufacturing processes | |
| UA117556C2 (uk) | Спосіб збільшення ефективності терапевтичного засобу шляхом введення метотрексату | |
| MX370723B (es) | Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatía. | |
| PH12016500753B1 (en) | Antibodies specific to fcrn | |
| EA201790439A1 (ru) | Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами | |
| PH12018501443A1 (en) | Methods of administering hepcidin | |
| EA201790563A1 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. | |
| MX2025003476A (es) | Anticuerpos anti-il-27 y usos de los mismos | |
| EA201691020A1 (ru) | Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина" | |
| EA202090260A1 (ru) | Средства и способы для генотерапии aav у человека | |
| EA201992875A1 (ru) | T-клетки со сниженным поверхностным фукозилированием и способы их получения и применения |